KOMZIFTI
LaunchSMziftomenib
NDAORALCAPSULEPriority Review
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
11
Mechanism of Action
Menin Inhibitors
Pharmacologic Class:
Menin Inhibitor
Clinical Trials (5)
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
Started Jul 2026
24 enrolled
KMT2A-rearrangedNPM1-mutant Refractory or Relapsed AML
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Started Apr 2026
70 enrolled
Acute Myeloid Leukemia
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Started Sep 2025
1,300 enrolled
Acute Myeloid Leukemia (AML)
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Started Mar 2025
157 enrolled
Gastrointestinal Stromal Tumor (GIST)Gastrointestinal Stromal CancerGastrointestinal Stromal Neoplasm+2 more
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Started Mar 2025
20 enrolled
Relapsed/Refractory KMT2A-r Acute LeukemiaRelapsed/Refractory NUP98-r Acute LeukemiaRelapsed/Refractory NPM1-m Acute Leukemia
Loss of Exclusivity
LOE Date
Jul 16, 2044
223 months away
Patent Expiry
Jul 16, 2044
Exclusivity Expiry
Nov 13, 2030